Home / Knowledge Centre /

Biocatalysis Development: Ered Assay Development and Naphthol Synthesis

Ene-reductases (EREDs) of the flavin dependent Old Yellow Enzyme (OYE) family catalyse the formal trans addition of molecular hydrogen to activated C=C bonds and have found applications in the synthesis of chiral synthons for the pharmaceutical industry.[1] This is achieved by delivery of a proton to Cα, via a structurally conserved Tyr residue and hydride delivery to Cβ, from reduced FMN. Typically, the hydride is derived from a nicotinamide cofactor but alternative hydride sources, in the form of sacrificial co-substrates, have been well studied.
In the current study, a fluorescence-based assay was developed for the detection of 2-naphthol during the ERED-catalysed reduction of a model substrate. This facile assay was applied to Almac’s in-house panel of EREDs revealing a range of activities, including many promising hits. Several of these hit enzymes were then challenged with a panel of substituted tetralones, resulting in the efficient production of the equivalent naphthols derived from tetralones 1-8.

View Resource
Almac Logo

Almac API, Chemical Development, Analytical & Solid State Services

Almac Sciences provides integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).

We provide a range of services for small molecules (including highly potent) and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.

Learn More

We offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances.

Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies